TY - JOUR
T1 - Post-traumatic Headache
T2 - Pharmacologic Management and Targeting CGRP Signaling
AU - Ashina, Håkan
AU - Dodick, David W
N1 - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - PURPOSE OF REVIEW: Post-traumatic headache is a common sequela of injury to the head and/or neck. Here, we review the current approach to pharmacologic management of post-traumatic headache and explore the therapeutic promise of targeting calcitonin gene-related peptide signaling to address unmet treatment needs.RECENT FINDINGS: The scarcity of data from controlled trials has left clinicians to rely on mainly expert opinion for the pharmacologic management of post-traumatic headache. The current view is that a phenotype-guided approach should be used, in which patients are treated according to the primary headache phenotype that their clinical features resemble the most (e.g. migraine, tension-type headache). Moreover, incremental advances are being made in the field that aim to identify possible cellular and molecular drivers of headache persistence. Calcitonin gene-related peptide has emerged as a key drug target which, in turn, has prompted novel insights on the potential importance of early initiation of pharmacologic treatment following the onset of post-traumatic headache. This, in turn, might prevent subsequent persistence and chronification of headache.
AB - PURPOSE OF REVIEW: Post-traumatic headache is a common sequela of injury to the head and/or neck. Here, we review the current approach to pharmacologic management of post-traumatic headache and explore the therapeutic promise of targeting calcitonin gene-related peptide signaling to address unmet treatment needs.RECENT FINDINGS: The scarcity of data from controlled trials has left clinicians to rely on mainly expert opinion for the pharmacologic management of post-traumatic headache. The current view is that a phenotype-guided approach should be used, in which patients are treated according to the primary headache phenotype that their clinical features resemble the most (e.g. migraine, tension-type headache). Moreover, incremental advances are being made in the field that aim to identify possible cellular and molecular drivers of headache persistence. Calcitonin gene-related peptide has emerged as a key drug target which, in turn, has prompted novel insights on the potential importance of early initiation of pharmacologic treatment following the onset of post-traumatic headache. This, in turn, might prevent subsequent persistence and chronification of headache.
KW - Calcitonin Gene-Related Peptide
KW - Headache
KW - Humans
KW - Migraine Disorders/drug therapy
KW - Post-Traumatic Headache/drug therapy
KW - Tension-Type Headache
KW - Traumatic brain injury
KW - Treatment
KW - Concussion
KW - Secondary headache disorders
UR - http://www.scopus.com/inward/record.url?scp=85124571745&partnerID=8YFLogxK
U2 - 10.1007/s11910-022-01175-w
DO - 10.1007/s11910-022-01175-w
M3 - Review
C2 - 35138589
SN - 1528-4042
VL - 22
SP - 105
EP - 111
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 2
ER -